Gastrosidin: instructions for use and reviews
Latin name: Gastrosidin
ATX code: A02BA03
Active substance: famotidine
Manufacturer: ZENTIVA (Türkiye)
Updating the description and photo: 26.08.2019
Gastrosidin is an H2-histamine receptor blocker, an antiulcer drug.
Release form and composition
Gastrosidin is available in the form of film-coated tablets: light beige, biconvex round, tablet core - white(10 pieces in a blister, 1 or 3 blisters in a cardboard box).
1 tablet contains:
- active ingredient: famotidine – 0.02 or 0.04 g;
- auxiliary components: corn starch, magnesium stearate, lactose, colloidal silicon dioxide;
- shell composition: propylene glycol 6000, hypromellose, hydroxypropylcellulose, titanium dioxide, yellow iron oxide, red iron oxide, talc.
Pharmacological properties
Pharmacodynamics
The active substance of Gastrosidine is famotidine, a third-generation H2-histamine receptor blocker.
The drug suppresses the production of hydrochloric acid, both basal and stimulated by histamine, acetylcholine and gastrin. Reduces pepsin activity. Strengthens defense mechanisms gastric mucosa. Increases the formation of gastric mucus and the content of glycoproteins in it, stimulates the secretion of bicarbonate by the gastric mucosa, increases the endogenous synthesis of prostaglandins in it and the rate of regeneration, due to which Gastrosidin helps heal damage to the gastric mucosa associated with the effects of hydrochloric acid (including helping to stop gastrointestinal bleeding and scarring of stress ulcers).
Famotidine has no significant effect on plasma gastrin concentrations. It weakly inhibits the cytochrome P 450 oxidase system in the liver.
The effect of Gastrosidin begins 1 hour after oral administration, reaches a maximum within 3 hours, and persists for 12–24 hours (depending on the dose) after a single dose.
Pharmacokinetics
After administration, famotidine enters the gastrointestinal tract, from where it is quickly absorbed. Reaches maximum concentration in blood plasma within 1–3.5 hours. The bioavailability of the drug is 40–45%, increases when taking tablets with food, and decreases in the case of simultaneous use of antacids.
The connection with plasma proteins is low – 15–20%. Famotidine penetrates the placental barrier and into breast milk.
About 30–35% of the received dose of famotidine is metabolized in the liver to form S-oxide. It is excreted primarily through the kidneys with urine unchanged (27–40%). The half-life (T ½) is 2.5–4 hours, in patients with creatinine clearance (CC) 10–30 ml/min increases to 10–12 hours, with CC< 10 мл/мин – до 20 ч.
Indications for use
- treatment and prevention of relapse peptic ulcer stomach and duodenum;
- treatment and prevention of symptomatic ulcers of the stomach and duodenum that occur due to stress, taking non-steroidal anti-inflammatory drugs (NSAIDs), and undergoing surgical operations;
- functional dyspepsia associated with increased secretory function stomach;
- erosive gastroduodenitis;
- reflux esophagitis;
- Zollinger-Ellison syndrome;
- prevention of recurrent bleeding from the upper sections gastrointestinal tract(GIT);
- Mendelssohn's syndrome - prevention of exposure gastric juice V Airways when conducting general anesthesia.
Contraindications
- liver failure;
- period of pregnancy and breastfeeding;
- childhood;
- individual intolerance to the components of the drug.
According to the instructions, Gastrosidin should be prescribed with caution in cases of impaired liver function, liver cirrhosis with a history of portosystemic encephalopathy, or renal failure.
Instructions for use of Gastrosidin: method and dosage
Gastrosidin tablets are taken orally, swallowed whole and washed down with a sufficient amount of water.
- exacerbation of gastric and duodenal ulcers, symptomatic ulcers, erosive gastroduodenitis: 20 mg 2 times a day or 40 mg 1 time a day (before bedtime). In the absence of sufficient therapeutic effect the daily dose can be increased to 80–160 mg. Duration of treatment – 28–56 days;
- dyspepsia caused by increased secretory function of the stomach: 20 mg 1-2 times a day;
- prevention of relapse of gastric and duodenal ulcers: 20 mg 1 time per day before bedtime;
- reflux esophagitis: 20-40 mg 2 times a day, course of treatment – 42–84 days;
- Zollinger-Ellison syndrome: initial dose is 20 mg every 6 hours, if necessary it can be increased to 160 mg every 6 hours. The dose and duration of therapy are determined individually;
- prevention of aspiration during general anesthesia: 40 mg in the evening (the day before surgery) or in the morning (immediately before surgery).
In renal failure with creatinine clearance less than 30 ml/min daily dose Gastrosidine should not exceed 20 mg.
Side effects
- from the outside of cardio-vascular system: decrease blood pressure, bradycardia, atrioventricular block;
- from the outside digestive system: loss of appetite, dry mouth, abdominal pain, nausea, vomiting, increased activity of liver enzymes, acute pancreatitis, hepatitis;
- from the hematopoietic organs: rarely – thrombocytopenia, leukopenia; very rarely - agranulocytosis, hypoplasia, pancytopenia, bone marrow aplasia;
- from the outside nervous system: hallucinations, dizziness, headache, confusion;
- from the outside reproductive system: against the background of long-term use of high doses of Gastrosidin - decreased libido, hyperprolactinemia, amenorrhea, gynecomastia, impotence;
- from the senses: ringing in the ears, accommodation paresis, blurred visual perception;
- allergic reactions: dry skin, itchy skin, rash, urticaria, angioedema, bronchospasm, anaphylactic shock;
- other: rarely - arthralgia, myalgia, fever.
Overdose
Possible symptoms of Gastrosidine overdose: vomiting, tremor, motor agitation, tachycardia, decreased blood pressure, collapse.
Treatment is symptomatic.
special instructions
The use of Gastrosidine should be started only after exclusion malignant neoplasm in the esophagus, stomach or duodenum.
It is advisable to discontinue the drug by gradually reducing the daily dose, since sudden cessation of therapy can cause rebound syndrome.
Long-term treatment of weakened patients can contribute to bacterial damage to the stomach and the spread of infection.
During the treatment period, the patient is advised to follow a diet that excludes the consumption of foods and drinks that cause irritation of the gastric mucosa. You should also avoid taking medicines irritating to the digestive system.
Gastrosidine may interfere with the effects of histamine and pentagastrin on gastric acid-related function, so it is recommended that you stop taking it 24 hours before the test.
In addition, H2-histamine receptor blockers can suppress the immediate skin reaction to histamine to obtain reliable results diagnostic samples If an allergic skin reaction is detected, it is necessary to temporarily stop using Gastrosidine.
Impact on the ability to drive vehicles and complex mechanisms
Caution should be exercised when potentially dangerous species activities, including management vehicles and other mechanisms.
Use during pregnancy and lactation
Gastrosidin is contraindicated for use during pregnancy and breastfeeding.
Use in childhood
The drug is not used in pediatric practice.
For impaired renal function
Gastrosidine tablets should be used with caution in case of renal failure.
For liver dysfunction
Gastrosidine should be used with extreme caution in patients with impaired liver function and cirrhosis with a history of portosystemic encephalopathy.
In case of severe liver failure, taking the drug is contraindicated.
Drug interactions
With simultaneous use of Gastrosidin:
- ketoconazole, itraconazole reduce their absorption;
- sucralfate, antacids help reduce the intensity of absorption of the drug; if this combination is necessary, the break between taking these drugs and famotidine should be 1–2 hours;
- amoxicillin, clavulanic acid increase their absorption;
- drugs that have an inhibitory effect on Bone marrow, increase the risk of developing neutropenia.
Analogs
Analogues of Gastrosidine are: Kvamatel, Ulfamid, Famosan, Famotidine.
Terms and conditions of storage
Keep away from children.
Store at temperatures up to 30 °C.
Shelf life – 4 years.
One tablet contains
active substance - famotidine 40 mg,
excipients: lactose (monohydrate), corn starch, colloidal anhydrous silicon dioxide, magnesium stearate,
shell composition: SeleCoat AQ-1257, brown: hydroxypropyl methylcellulose, hydroxypropylcellulose, polyethylene glycol 6000, iron (III) oxide red (E172), iron (III) oxide yellow (E172), talc, titanium dioxide (E171).
Description
Round tablets, with a biconvex surface, film-coated, light Brown, with a risk on one side.
Pharmacotherapeutic group
Antiulcer drugs and drugs for the treatment of gastroesophageal reflux. H2-histamine receptor blockers. Famotidine.
ATX code A02BA03
Pharmacological properties"type="checkbox">
Pharmacological properties
Pharmacokinetics
After oral administration of 40 mg famotidine, the maximum plasma concentration after 1 to 3.5 hours is 78 mcg/l, and the therapeutic level is maintained for 24 hours.
The bioavailability of the drug is about 45%. The degree of binding to blood plasma proteins is 15 – 22%.
Famotidine is excreted from the body mainly by the kidneys (65-70%), 30-35% of the drug is excreted through the intestines. 25-30% of the dose taken is excreted unchanged from the body in the urine.
In patients with normal function kidney elimination half-life is 2.5–4 hours; in patients with creatine clearance lower than 30 ml/min, it increases to 10–12 hours.
Pharmacodynamics
Gastrosidin is a competitive antagonist of H-2 histamine receptors
3rd generation long-acting. Oral administration of Gastrosidine at a dose of 10 - 20 mg leads to a decrease in the secretion of hydrochloric acid by more than 80%, at least for 12 hours. The plasma concentration of famotidine required for 50% suppression of gastric acid secretion is 13 µg/l.
After taking 40 mg of Gastrosidin, the acid pH in the stomach is 5.0 – 6.4.
Inhibition of hydrochloric acid secretion by Gastrosidin may slightly increase the concentration of gastrin in the blood serum to upper limits normal indicators.
Gastrosidin suppresses both basal and pentagastrin-stimulated hydrochloric acid secretion.
The drug has a wide therapeutic index, which allows it to maintain its effectiveness even with long-term use in high doses.
In patients with Zollinger-Ellison syndrome, with long-term use of Gastrosidin in combination with anticholinergic drugs that control the secretion of hydrochloric acid in the stomach, no changes in biochemical blood parameters were observed.
Gastrosidin is well tolerated by patients.
Indications for use
Treatment and prevention of gastric and duodenal ulcers
Pathological conditions associated with increased secretion of hydrochloric acid (Zollinger-Ellison syndrome)
Gastroesophageal reflux disease (GERD)
Prevention of erosive and ulcerative lesions of the gastrointestinal tract while taking non-steroidal anti-inflammatory drugs (NSAIDs).
Directions for use and doses
Gastric and duodenal ulcers in the acute phase -
40 mg of the drug at night. The duration of treatment is 4 – 8 weeks, depending on the dynamics of healing (scarring) of the ulcer.
Prevention of relapses of gastric and duodenal ulcers
To prevent relapses of gastric and duodenal ulcers, it is recommended to take Gastrosidin at a dose of 20 mg once a day before bedtime for 4-8 weeks.
Zollinger-Ellison syndrome
For patients who have not previously received drugs that suppress secretion, it is recommended to use Gastrosidine at an initial dose of 20 mg every 6 hours. The dose should be prescribed depending on the patient's condition and treatment should be continued in accordance with clinical indicators. Moreover, the daily dose of the drug in these patients can reach 400 mg without side effects.
For gastroesophageal reflux disease (GERD), the recommended oral dose is 20 mg twice daily, with a treatment duration of 6-12 weeks. In cases where GERD is accompanied by esophagitis, the recommended dose of Gastrosidin is 20-40 mg for 12 weeks.
Prevention of erosive and ulcerative lesions of the gastrointestinal tract while taking non-steroidal anti-inflammatory drugs (NSAIDs)
20 mg 1 time per day before bedtime for the duration of taking non-steroidal anti-inflammatory drugs (NSAIDs).
Method of administration and dosage in special groups of patients
Kidney failure
Since Gastrosidin is primarily excreted by the kidneys, it should be used with caution in patients with renal failure. If creatinine clearance<30 мл/мин, а уровень сывороточного креатинина >3 mg/ml, the maximum daily dose should be reduced to 20 mg per day or the interval between doses should be increased to 36-48 hours.
Side effects"type="checkbox">
Side effects
Lack of appetite, dry mouth, disorders taste sensations, nausea, vomiting, bloating, diarrhea or constipation
Headache, dizziness, fatigue, tinnitus, transient mental disorders
Possible muscle pain, joint pain
Skin itching, bronchospasm, fever, alopecia, acne vulgaris, dry skin, angioedema, anaphylactic shock, other manifestations of hypersensitivity
Convulsions
Mental disorders
Leukopenia, thrombocytopenia
Arrhythmia, atrioventricular block
Increased liver enzyme activity, hyperbilirubinemia, increased urea levels
Development of cholestatic jaundice
Very rarely
Agranulocytosis, pancytopenia
With long-term use - hyperprolactinemia, gynecomastia, amenorrhea, decreased libido, impotence.
Contraindications
Increased sensitivity to famotidine and other components of the drug
Pregnancy and lactation
Hereditary fructose intolerance, Lapp-lactase enzyme deficiency, glucose-galactose malabsorption
Children's and adolescence up to 18 years old
Drug interactions"type="checkbox">
Drug interactions
With the simultaneous use of famotidine with anticoagulants, the possibility of an increase in prothrombin time and the development of bleeding cannot be excluded.
With simultaneous use of famotidine with antacids containing magnesium hydroxide and aluminum hydroxide, the absorption of famotidine may be reduced.
With the simultaneous use of famotidine with itraconazole, it is possible to reduce the concentration of itraconazole in the blood plasma and reduce its effectiveness.
With the simultaneous use of famotidine with nifedipine, a case of a decrease in cardiac output and cardiac output, due to the increased negative ionotropic effect of nifedipine.
With simultaneous use of famotidine with norfloxacin, the concentration of norfloxacin in the blood plasma decreases, and with probenecid, the concentration of famotidine in the blood plasma increases.
With simultaneous use of famotidine with cyclosporine, a slight increase in the concentration of cyclosporine in the blood plasma is possible.
With simultaneous use, famotidine reduces the absorption of ketoconazole.
special instructions"type="checkbox">
special instructions
Use with caution in patients with impaired renal and liver function.
Patients with severe renal failure (creatinine clearance<10 мл/мин) рекомендуется более длинные интервалы между дозами или более низкие дозы.
Before starting treatment, it is necessary to exclude the possibility of a malignant disease of the esophagus, stomach or duodenum. Does not change the activity of microsomal liver enzymes.
- high bioavailability of the drug;
- rapid accumulation in the body and the provision of a therapeutic effect;
- delayed half-life of the drug from the body.
Flaws:
- one form of release of the drug in film-coated tablets of 20 mg;
- Compared to analogues, the price of the drug is high.
Film-coated tablets 40 mg, blister 10, box 3
*** rub.
* The maximum permissible retail price of medicines is indicated, calculated in accordance with Decree of the Government of the Russian Federation No. 865 of October 29, 2010 (For those medicines that are on the list)
Instructions for use:
The tablets are taken orally, 30 minutes before meals or 1.5-2 hours after meals, with a small amount of water 1-2 times a day.
For the treatment of GERD, gastritis and erosive gastroduodenitis, the drug is prescribed 20-40 mg 1-2 times a day. The maximum daily dose is 120 mg.
For the treatment of gastric and duodenal ulcers, the drug is prescribed 40 mg once a day at night or 20 mg 2 times a day (morning and evening). The maximum daily dose of the drug for this disease is 120-140 mg.
For the treatment of Zollinger-Ellison syndrome, the drug is prescribed 40 mg every 5-6 hours (4 times a day). The maximum daily dose of the drug is 240-480 mg.
To prevent bleeding from the upper gastrointestinal tract, the drug is prescribed 20 mg once a day at night.
For the treatment of systemic mastocytosis and polyendocrine adenomatosis, the drug is prescribed 80 mg 3 times a day. The maximum daily dose of the drug for these diseases is 480 mg.
To prevent Mendelssohn's syndrome, the drug is prescribed 40 mg 1 day before surgery or, immediately in the morning, on the day of surgery.
The duration of treatment is individual and is decided on a case-by-case basis by the attending physician.
For patients suffering from chronic renal failure with severe impairment of organ function, the drug is prescribed with caution in a dose not exceeding 20 mg once a day.
The drug is not prescribed during pregnancy and breastfeeding.
Prescription of the drug is prohibited for children under 18 years of age.
comparison table
Drug name | Bioavailability, % | Bioavailability, mg/l | Time to reach maximum concentration, h | Half-life, h |
Gastrosidin | ||||
pharmachologic effect
Gastrosidin is a drug used to treat peptic ulcers. Gastrosidine contains famotidine, an inhibitor of H2-histamine receptors, which, unlike other known drugs in this group, contains a substituted thiazole ring in its structure.
Famotidine blocks the effect of histamine on H2-specific receptors, as a result of which gastric secretion of hydrochloric acid (including stimulated and basal) decreases.
Famotidine weakly dissociates in complex with H2 receptors, which ensures its effectiveness. When inhibiting stimulated production of hydrochloric acid, famotidine is more active in a molar ratio than ranitidine and cimetidine (3-20 and 20-150 times, respectively).
Famotidine is used in hyperacid conditions and to reduce gastric secretion in case of ulcerative damage to the duodenal mucosa, as well as gastroesophageal reflux.
Pharmacokinetics
After oral administration, famotidine is rapidly absorbed and reaches peak serum levels 1–2 hours after administration. The half-life of famotidine is 2–3 hours. Average bioavailability is 40–50% (individual variability is possible).
Famotidine is excreted predominantly by the urinary system (65–70%) unchanged.
Indications for use
Gastrosidin is used in the treatment of patients with ulcers (peptic) of the duodenum and stomach. Gastrosidine may also be used as a prophylactic agent to prevent recurrence of these conditions.
Gastrosidin can also be used for ulcerative lesions of the mucous membranes of the stomach and duodenum of various etiologies, including stress and drug ulcers.
Gastrosidin is used in complex therapy of patients with functional dyspepsia, as well as Zollinger-Ellison syndrome.
Gastrosidin tablets are used in the treatment of patients with reflux esophagitis and erosive esophagitis.
In patients at high risk of upper gastrointestinal bleeding, Gastrosidin tablets can be used as prophylaxis.
Mode of application
Gastrosidin tablets are taken orally. The dosage of the drug should be selected by a specialist, taking into account the indications and the necessary concomitant therapy. Before prescribing Gastrosidin tablets, the doctor must conduct research to exclude the malignant nature of the pathology.
Dosing of Gastrosidin tablets for peptic ulcers
For a benign ulcer that is associated with Helicobacter pylori, prescribe 1 Gastrosidin tablet per day (in the evening, before going to bed) in combination with clarithromycin at a dose of 500 mg/twice a day and amoxicillin at a dose of 1 g/twice a day.
The average duration of taking Gastrosidin tablets is 4–8 weeks.
An alternative is to prescribe famotidine 20 mg/twice daily.
As a prophylactic agent, Gastrosidin tablets are prescribed at a dose of 20 mg/day before bedtime every day.
Dosing of Gastrosidin tablets for gastroesophageal reflux
Adult patients with gastroesophageal reflux are usually prescribed 20 mg of famotidine twice a day.
The average duration of treatment is 6–12 weeks.
In the presence of concomitant esophageal ulcer, the dose of famotidine is recommended to be increased to 40 mg/twice daily.
Dosing of Gastrosidin tablets for functional dyspepsia
Patients with functional dyspepsia that is not associated with an ulcer are usually recommended to take 20 mg of famotidine 1-2 times a day.
Dosing of Gastrosidine tablets for Zollinger–Ellison syndrome
In Zollinger-Ellison syndrome, the amount of famotidine and the frequency of administration are selected by a specialist individually, the starting dose is 20 mg of famotidine every 4–6 hours. There is data on the use of famotidine in patients with Zollinger-Ellison syndrome in a daily dose of up to 800 mg.
Side effects
Gastrosidine was generally well tolerated by patients. Adverse events during therapy in most patients are mild and do not require discontinuation of famotidine.
During the studies, the development of stool disorders, vomiting, excessive gas formation in the intestines, as well as headache, thrombocytopenia and leukopenia, skin rash and increased activity of liver transaminases when taking famotidine were most often recorded.
In isolated situations, the following undesirable effects may occur:
Gastrointestinal tract: abdominal pain, dry mouth, hepatitis, loss of appetite, acute pancreatitis.
CNS: confusion, hallucinations.
CVS: bradycardia, atrioventricular block, arterial hypotension.
Blood system: pancytopenia, agranulocytosis, bone marrow aplasia or hypoplasia.
Reproductive system: gynecomastia, hyperprolactinemia, decreased libido, erectile dysfunction, amenorrhea. Adverse events from the reproductive system were observed only in patients who took high doses of famotidine for a long time.
Sense organs: ringing in the ears, decreased visual acuity, accommodation paresis.
In patients with hypersensitivity, allergic reactions, including anaphylactic reactions, may occur.
If severe adverse events occur, you should stop taking Gastrosidin tablets and consult a specialist.
Contraindications
Gastrosidine is contraindicated in patients with intolerance to famotidine or the auxiliary components of the tablets.
Gastrosidin is not used in pediatric practice.
It is recommended to exercise caution when prescribing Gastrosidin tablets to patients with impaired liver function, as well as a history of liver cirrhosis and portosystemic encephalopathy.
Gastrosidine is prescribed with caution to patients with renal failure.
Pregnancy
There is no data on the safety of famotidine for the fetus. During pregnancy, the prescription of famotidine is possible only by the doctor's decision and in cases where a safer drug cannot be prescribed.
During lactation, taking Gastrosidin tablets is not advisable.
Drug interactions
Gastrosidine should not be used simultaneously with antacid medications (the patient should maintain a break of at least 1-2 hours between taking famotidine and antacids).
Gastrosidin may affect the pharmacokinetic profile and bioavailability of oral drugs, the absorption of which depends on the acidity of the gastric contents.
Overdose
When taking excessive doses of famotidine, patients are likely to experience vomiting, diarrhea and nausea. In case of severe overdose of the drug Gastrosidin, tremor, motor agitation, tachycardia and severe hypotension (up to collapse) may occur.
In case of an overdose of Gastrosidin tablets, it is necessary to rinse the patient’s stomach and prescribe oral sorbents. If necessary, specific therapy is used to relieve signs of overdose.
Release form
Gastrosidin coated tablets, packaged in blister plates, 30 tablets in a cardboard box.
Storage conditions
Gastrosidine should be stored out of the reach of children at room temperature.
Tablets should be stored away from direct sunlight in their original packaging.
Shelf life – 4 years.
Compound
1 tablet of Gastrosidin contains:
Famotidine – 40 mg.
Other ingredients: corn starch, magnesium stearate, lactose, colloidal anhydrous silica, hydroxypropylcellulose, hydroxypropylmethylcellulose, red and yellow iron oxide, titanium dioxide, talc, polyethylene glycol.
Pharmacological group
Medicines used for diseases of the gastrointestinal tract
Medicines used to treat gastric and duodenal ulcers
H2-histamine receptor blockers
Nosological classification (ICD-10)
Stomach ulcer (K25)
Duodenal ulcer (K26)
Other diseases of the stomach and duodenum (K31)
Zollinger-Ellison syndrome (K86.8.3*)
Active substance: Famotidine
ATX: A02B A03
Manufacturer: Zentiva
Additional information about the manufacturer
Country of origin: Türkiye.
Additionally
Gastrosidine, like other histamine H2 receptor inhibitors, should not be abruptly discontinued (due to the likelihood of rebound syndrome).
Famotidine may reduce the severity of the skin reaction to histamine and lead to false-negative skin test results. You should stop taking Gastrosidin tablets several days before the planned allergy tests.
When carrying out therapy with Gastrosidin tablets, it is recommended to avoid eating spicy and sour foods, which can lead to irritation of the gastric mucosa and stimulate additional secretion of gastric juice.
Until your personal reaction to famotidine is determined, you should refrain from driving.
Latest update of the description by the manufacturer 31.07.1998
Filterable list
Active substance:
ATX
Pharmacological group
Nosological classification (ICD-10)
Composition and release form
1 film-coated tablet contains famotidine 40 mg; per package 3 blisters of 10 pcs.
pharmachologic effect
pharmachologic effect- antiulcer.Blocks histamine H2 receptors.
Pharmacokinetics
After oral administration, Cmax in plasma is 1-3.5 hours, protein binding is 15-22%. Bioavailability - 37-45%, volume of distribution - 1.1-1.4 l/kg. It is excreted from the body in urine and bile, about 25-30% of the drug is excreted unchanged in the urine. In patients with normal renal function T1/2 is 2.5-4 hours.
Clinical pharmacology
After a single dose, the effect lasts 12 hours. It inhibits the release of hydrochloric acid in the stomach (both basal and stimulated by pentagastrin, tetragastrin or betazole). Taking 40 mg once daily, Gastrosidin reduces nocturnal secretion by an average of 94%. Promotes scarring of stomach and duodenal ulcers. Does not affect the activity of the liver monooxygenase system and the secretion of prolactin, does not have an antiandrogenic effect.
Indications for the drug Gastrosidin
Duodenal ulcer and benign gastric ulcer (prevention of exacerbations and treatment), pathological conditions associated with increased secretion (including Zollinger-Ellison syndrome).
Contraindications
Hypersensitivity.
Side effects
Headache, dizziness, disorientation, constipation, increased serum transaminase levels.
Directions for use and doses
Orally, for the treatment of gastric and duodenal ulcers - 40 mg at night for up to 4 weeks (if there is no effect - up to 8 weeks), for the prevention of exacerbations - 20 mg at night for 6 months, for Zollinger-Ellison syndrome - 20 mg every 6 hours (maximum daily dose - 400 mg).
Precautionary measures
Before starting treatment, it is necessary to ensure that the ulcer is benign. Pregnant women and after childbirth are prescribed in the presence of strict indications and under the supervision of a doctor.
Storage conditions for the drug Gastrosidin
At temperatures below 30 °C (do not freeze).Keep out of the reach of children.
Shelf life of the drug Gastrosidin
4 years.Do not use after the expiration date stated on the package.
Synonyms of nosological groups
| Category ICD-10 | Synonyms of diseases according to ICD-10 |
|---|---|
| K25 Stomach ulcer | Helicobacter pylori |
| Pain syndrome with gastric ulcer | |
| Inflammation of the gastric mucosa | |
| Inflammation of the gastrointestinal mucosa | |
| Benign gastric ulcer | |
| Exacerbation of gastroduodenitis against the background of peptic ulcer | |
| Exacerbation of peptic ulcer | |
| Exacerbation of gastric ulcer | |
| Organic gastrointestinal disease | |
| Postoperative gastric ulcer | |
| Ulcer recurrence | |
| Symptomatic stomach ulcers | |
| Helicobacteriosis | |
| Chronic inflammatory disease of the upper gastrointestinal tract associated with Helicobacter pylori | |
| Erosive and ulcerative lesions of the stomach | |
| Erosive lesions of the stomach | |
| Erosion of the gastric mucosa | |
| Peptic ulcer | |
| Stomach ulcer | |
| Gastric ulcer | |
| Ulcerative lesions of the stomach | |
| K26 Duodenal ulcer | Pain syndrome in duodenal ulcer |
| Pain syndrome in gastric and duodenal ulcers | |
| Disease of the stomach and duodenum associated with Helicobacter pylori | |
| Exacerbation of peptic ulcer | |
| Exacerbation of duodenal ulcer | |
| Peptic ulcer of the stomach and duodenum | |
| Recurrence of duodenal ulcer | |
| Symptomatic ulcers of the stomach and duodenum | |
| Helicobacteriosis | |
| Helicobacter pylori eradication | |
| Erosive and ulcerative lesions of the duodenum | |
| Erosive and ulcerative lesions of the duodenum associated with Helicobacter pylori | |
| Erosive lesions of the duodenum | |
| Duodenal ulcer | |
| Ulcerative lesions of the duodenum | |
| K31 Other diseases of the stomach and duodenum | Discomfort in the stomach area |
| Stress damage to the mucous membrane | |
| K86.8.3* Zollinger-Ellison syndrome | Ulcerogenic pancreatic adenoma |
| Gastrinoma | |
| Gastrinomas | |
| Zollinger-Ellison syndrome |
